WALTHAM, Mass. — CellTivity Scientific announced that its Van Gogh Microscopy System has been used in more than 10,000 patient procedures, marking a milestone as the company expands adoption of its Dynamic Cell Imaging technology in the United States and internationally.
The Van Gogh system provides real-time cellular imaging to help physicians assess tissue during medical procedures. The technology allows clinicians to examine cellular structure and activity in fresh tissue while preserving specimens for subsequent laboratory and molecular analysis.
More than 60 health systems worldwide have adopted the technology, with several clinical programs surpassing 1,000 patient procedures.
“Reaching 10,000 patient procedures is an important milestone for CellTivity, but what is most meaningful is what we are seeing behind that number,” said CellTivity CEO Greg Bowles. “Multiple programs have now surpassed 1,000 procedures, demonstrating continued utilization of Van Gogh within established clinical workflows.”
Bowles said the company is also expanding internationally and seeing increased interest in its technology across additional medical specialties.
Van Gogh received its CE mark in Europe in late 2025, enabling commercial availability in European markets and expanding access to real-time cellular imaging technology.
Initially focused on lung cancer, CellTivity is extending the system’s applications into gastrointestinal, pancreatic and gynecologic oncology procedures.
In pancreatic cancer assessment, physicians are using Van Gogh during advanced endoscopic procedures, including endoscopic ultrasound, to evaluate tissue samples in real time. The technology provides additional cellular information during specimen collection and assessment.
The company is also exploring applications in gynecologic oncology, where published research has examined the system’s ability to provide microscopic assessments of lymph node tissue during cancer surgery.
“The growth we are seeing across our established U.S. and European customers as well as new clinical applications confirms that Van Gogh reaches well beyond a single procedure or specialty,” Bowles said.
As CellTivity prepares for its next funding round, the company plans to expand its installed base, strengthen clinical partnerships and generate additional evidence supporting the technology’s use across multiple cancer types.
The company said its priorities include increasing utilization among existing customers, expanding internationally and advancing research into potential applications in lung, pancreatic, gastrointestinal and gynecologic cancers.
